Cravath – Mylan’s $35 Billion Proposed Acquisition of Perrigo

On April 8, 2015, Mylan N.V. announced that it has made a proposal to acquire Perrigo Company plc in a cash‑and‑stock transaction that would create a unique global pharmaceutical leader. Cravath is representing Mylan in connection with this proposed transaction. Under the terms of the non‑binding proposal, Perrigo shareholders would receive $205 in a combination of cash and Mylan stock for each Perrigo share, representing a total enterprise value of approximately $35 billion.

The Cravath team is being led by partners Mark I. Greene, Scott A. Barshay and Aaron M. Gruber and includes associate Jacquelyn N. Arcati on M&A matters; partners William V. Fogg and Johnny G. Skumpija on securities matters; partner George E. Zobitz and associate C. Daniel Haaren on banking matters; partners Stephen L. Gordon and J. Leonard Teti II and associates Kara L. Mungovan and Stephen R. Severo on tax matters; partner Eric W. Hilfers and associate Jonathan J. Katz on executive compensation and benefits matters; partner Christine A. Varney, practice area attorney Robin C. Landis and associate Margaret Segall D’Amico on regulatory matters; and senior attorney Kimberley S. Drexler on corporate matters. Lee M. Blum is also working on M&A matters and Kiran Sheffrin is also working on tax matters.

Source:  www.cravath.com